"Viking Therapeutics' Breakthrough Weight Loss Drug Sparks Investor Frenzy"

Viking Therapeutics has emerged as a strong contender in the weight loss drug market, with its experimental obesity treatment showing promising results in a midstage trial, leading to a 120% surge in its shares. Analysts believe the company's injectable drug may be "best-in-class," outperforming competitors like Eli Lilly and Novo Nordisk. However, Viking still faces challenges in manufacturing and regulatory approval, and its drug may not reach the market until 2029. Despite this, the company's impressive data has made it an attractive target for potential partnerships or acquisitions by larger pharmaceutical companies looking to enter the weight loss drug market.